Skip to content
Inciteful Med

Introduction & Orientation to Steinert Myotonic Dystrophy (DM1)

Last updated:

Steinert Myotonic Dystrophy (DM1) is an inherited, multisystemic condition characterized by muscle weakness and myotonia (difficulty relaxing muscles). While symptoms vary and slowly progress, a multidisciplinary medical team can effectively manage the condition and monitor overall health.

Key Takeaways

  • • DM1 is the most common adult-onset muscular dystrophy and is caused by an inherited genetic mutation in the DMPK gene.
  • • Symptoms vary widely between individuals but often include muscle weakness, difficulty relaxing muscles (myotonia), and significant daytime fatigue.
  • • Because DM1 affects multiple body systems, care should be managed by a multidisciplinary team including neurologists, cardiologists, and pulmonologists.
  • • Early baseline screenings for heart and lung function are essential for long-term health, even if you are not currently experiencing symptoms.

Receiving a diagnosis of Myotonic Dystrophy Type 1 (DM1), also known as Steinert Disease, can feel overwhelming [1]. It is completely normal to feel anxious or uncertain as you begin to navigate this new information. Understanding the nature of the condition is the first step toward taking control of your health.

What is Myotonic Dystrophy Type 1?

DM1 is a multisystemic disorder, meaning it can affect many different parts of the body beyond just the muscles [2][3]. It is the most common form of muscular dystrophy that begins in adulthood [4][5].

The condition is autosomal dominant, which means the genetic trait is passed directly from parent to child [6]. If a parent has the DM1 gene, there is a 50% chance of passing it to each child [7]. It is caused by a small “glitch” in the DMPK gene, where a specific piece of DNA repeats itself more times than it should [5][8]. This creates “toxic” molecules that interfere with how your cells function [9]. Learn more about The Biology of DM1 and Your Genetic Report.

3 Stabilizing Facts

While a new diagnosis is a major life event, there are several reasons to feel grounded:

  1. Symptoms are highly variable: No two people experience DM1 in exactly the same way [10]. Symptoms can range from very mild to more significant, and they often progress slowly over many years [11].
  2. The mechanism is well-understood: Unlike many rare diseases, scientists know exactly which gene and which process cause DM1 [5]. This “roadmap” allows doctors to monitor for specific issues—like heart or lung changes—before they become serious [12][13].
  3. Active research is underway: There is a global effort to develop targeted therapies. Researchers are testing investigational treatments in clinical trials, such as Antisense Oligonucleotides (ASOs) and other experimental molecules (like AMPK activators) designed to “neutralize” the toxic genetic material [14][4]. (Note: These are experimental pharmacological treatments and not available as over-the-counter supplements).

The Importance of Specialized Care

DM1 is a rare condition, affecting approximately 1 in 8,000 people [1][15]. Because of its rarity, many local or general doctors may have limited experience with the specific needs of DM1 patients [1][16].

The most effective way to manage DM1 is through a multidisciplinary care team [17]. This is a group of specialists—including neurologists, cardiologists, and lung specialists (pulmonologists)—who work together to coordinate your Treatment Strategy [4][18]. Because DM1 can affect the heart’s rhythm and the muscles used for breathing, regular baseline screenings are essential for long-term health [19][7].

What the Path Looks Like

The typical course of DM1 involves a slow progression of muscle weakness and myotonia—a hallmark of the disease where muscles have difficulty relaxing after use (such as letting go of a doorknob) [18][20]. It can also impact energy levels, causing hypersomnolence (excessive daytime sleepiness) or significant fatigue [21][3]. Your path will also depend on which of the four Subtypes you fall into.

While there is currently no cure, much of the research agrees that endurance exercise is highly beneficial for maintaining strength [9][22]. Important: Because DM1 often affects the heart, you must get clearance from a cardiologist before starting any new exercise routine [23][22].

What remains uncertain is exactly how quickly symptoms will change for any one individual, which is why consistent follow-up with a knowledgeable medical team is your best tool for staying ahead of the condition [10][7].

Frequently Asked Questions

What is Steinert Myotonic Dystrophy (DM1)?
Steinert Myotonic Dystrophy, or DM1, is a genetic, multisystemic disorder that causes muscle weakness and difficulty relaxing muscles after use. It is the most common form of muscular dystrophy that begins in adulthood.
How is DM1 inherited?
DM1 is an autosomal dominant condition, meaning it can be passed directly from parent to child. If a parent carries the mutated DMPK gene, there is a 50% chance of passing the condition to each child.
What kind of doctors do I need to manage DM1?
Because DM1 affects many parts of the body, you will need a multidisciplinary care team. This typically includes a neurologist, cardiologist, and pulmonologist who work together to coordinate your treatment and monitor your health.
What baseline tests are needed after a DM1 diagnosis?
After a diagnosis, it is important to schedule baseline screenings for your heart and lungs, even if you do not have symptoms yet. These typically include an ECG or Holter monitor to check heart rhythm and pulmonary function tests to evaluate breathing.
Is exercise safe for someone with Steinert Disease?
Endurance exercise is generally considered beneficial for maintaining strength with DM1. However, because the condition can affect the heart, you must get clearance from a cardiologist before starting any new exercise routine.

Questions for Your Doctor

  • • Who will act as the lead coordinator or 'point person' for my multidisciplinary care?
  • • Which clinical subtype (congenital, childhood, adult, or late-onset) do my symptoms and genetic results most closely align with?
  • • Are you comfortable managing my care, or can you refer me to a specialized center with experience in myotonic dystrophy?
  • • Can we schedule baseline screenings for my heart (ECG/Holter monitor) and lungs (pulmonary function test), even if I don't have symptoms yet?
  • • Are there any current clinical trials or patient registries you would recommend I look into?

Questions for You

  • • What were the first symptoms that led you to seek a diagnosis, and how have they changed over time?
  • • Have you noticed any difficulty 'letting go' of objects like doorknobs or tools, or experienced unusual fatigue?
  • • Are there other family members who have had similar symptoms, even if they were never formally diagnosed?
  • • What are your primary goals for your health and lifestyle right now?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Heart transplantation in a patient with Myotonic Dystrophy type 1 and end-stage dilated cardiomyopathy: a short term follow-up.

    Papa AA, Verrillo F, Scutifero M, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2018; (37(4)):267-271.

    PMID: 30944906
  2. 2

    Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

    Meola G, Cardani R

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2017; (38(4)):535-546 doi:10.1007/s10072-016-2805-5.

    PMID: 28078562
  3. 3

    Central Nervous System Involvement as Outcome Measure for Clinical Trials Efficacy in Myotonic Dystrophy Type 1.

    Simoncini C, Spadoni G, Lai E, et al.

    Frontiers in neurology 2020; (11()):624 doi:10.3389/fneur.2020.00624.

    PMID: 33117249
  4. 4

    Myotonic dystrophy type 2: the 2020 update.

    Meola G

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):222-234 doi:10.36185/2532-1900-026.

    PMID: 33458578
  5. 5

    Myotonic Dystrophies: A Genetic Overview.

    Soltanzadeh P

    Genes 2022; (13(2)) doi:10.3390/genes13020367.

    PMID: 35205411
  6. 6

    Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

    Ait Benichou S, Jauvin D, De Serres-Bérard T, et al.

    Gene therapy 2022; (29(12)):698-709 doi:10.1038/s41434-022-00316-7.

    PMID: 35075265
  7. 7

    Sudden Death Caused by Bilateral Diaphragmatic Eventration in Myotonic Dystrophy Type 1.

    Wu S, Prahlow JA

    The American journal of forensic medicine and pathology 2025; (46(4)):330-336 doi:10.1097/PAF.0000000000001073.

    PMID: 40928346
  8. 8

    Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice.

    Jauvin D, Chrétien J, Pandey SK, et al.

    Molecular therapy. Nucleic acids 2017; (7()):465-474 doi:10.1016/j.omtn.2017.05.007.

    PMID: 28624222
  9. 9

    Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.

    Manta A, Stouth DW, Xhuti D, et al.

    The Journal of physiology 2019; (597(5)):1361-1381 doi:10.1113/JP277123.

    PMID: 30628727
  10. 10

    Factors Influencing the Severity and Progression of Respiratory Muscle Dysfunction in Myotonic Dystrophy Type 1.

    Hartog L, Zhao J, Reynolds J, et al.

    Frontiers in neurology 2021; (12()):658532 doi:10.3389/fneur.2021.658532.

    PMID: 33927684
  11. 11

    Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1.

    van der Plas E, Gutmann L, Thedens D, et al.

    Muscle & nerve 2021; (63(4)):553-562 doi:10.1002/mus.27174.

    PMID: 33462896
  12. 12

    Echocardiographic Features of Cardiac Involvement in Myotonic Dystrophy 1: Prevalence and Prognostic Value.

    Russo V, Capolongo A, Bottino R, et al.

    Journal of clinical medicine 2023; (12(5)) doi:10.3390/jcm12051947.

    PMID: 36902735
  13. 13

    Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.

    Gallinoro E, Papa AA, Rago A, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2018; (37(3)):227-231.

    PMID: 30838353
  14. 14

    Promising AAV.U7snRNAs vectors targeting DMPK improve DM1 hallmarks in patient-derived cell lines.

    Almeida CF, Robriquet F, Vetter TA, et al.

    Frontiers in cell and developmental biology 2023; (11()):1181040 doi:10.3389/fcell.2023.1181040.

    PMID: 37397246
  15. 15

    Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease modelling and therapeutic research.

    Pierre M, Jauvin D, Puymirat J, et al.

    Stem cell research 2024; (76()):103375 doi:10.1016/j.scr.2024.103375.

    PMID: 38490135
  16. 16

    [Medical emergency card for Steinert's disease: an unmet need].

    Rosado-Bartolomé A, Domínguez-González C

    Revista de neurologia 2023; (76(1)):15-19 doi:10.33588/rn.7601.2022380.

    PMID: 36544372
  17. 17

    Clinical and genetic characteristics of childhood-onset myotonic dystrophy.

    Stokes M, Varughese N, Iannaccone S, Castro D

    Muscle & nerve 2019; (60(6)):732-738 doi:10.1002/mus.26716.

    PMID: 31520483
  18. 18

    Myotonic Muscular Dystrophies.

    Johnson NE

    Continuum (Minneapolis, Minn.) 2019; (25(6)):1682-1695 doi:10.1212/CON.0000000000000793.

    PMID: 31794466
  19. 19

    Arrhythmic CArdiac DEath in MYotonic dystrophy type 1 patients (ACADEMY 1) study: the predictive role of programmed ventricular stimulation.

    Russo V, Papa AA, Rago A, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(7)):1148-1155 doi:10.1093/europace/euab282.

    PMID: 35861549
  20. 20

    Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.

    Rago A, Papa AA, Arena G, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2017; (36(4)):218-222.

    PMID: 29770366
  21. 21

    Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1.

    Miller JN, Kruger A, Moser DJ, et al.

    Frontiers in neurology 2021; (12()):700796 doi:10.3389/fneur.2021.700796.

    PMID: 34276551
  22. 22

    Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.

    Sharp L, Cox DC, Cooper TA

    Muscle & nerve 2019; (60(6)):779-789 doi:10.1002/mus.26709.

    PMID: 31509256
  23. 23

    Idiopathic ventricular fibrillation and the V1764fsX1786 frameshift mutation of the SCN5A gene in a myotonic dystrophy type 1 patient.

    Shimoyama T, Hayashi H, Suzuki F, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020; (74()):242-244 doi:10.1016/j.jocn.2020.02.007.

    PMID: 32063450

This page provides an introduction to Steinert Myotonic Dystrophy (DM1) for educational purposes only. Always consult your neurologist and multidisciplinary care team for personalized medical advice and symptom management.

Stay up to date

Get notified when new research about Steinert myotonic dystrophy is published.

No spam. Unsubscribe anytime.